Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SYS6055 injection in relapsed/refractory B-cell non-Hodgkin lymphoma
CTR20263849Phase 2Active
- Sponsor
- Beijing Kangchuanglian Biopharmaceutical Technology Research Center
- Start
- Oct 2026
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of SYS6055 in mature B-cell lymphoma, sponsored by Beijing Kangchuanglian Biopharmaceutical Technology Research Center. Started Oct 2026; status: active.
02
Drugs
SYS6055
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on CTR20263849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263849.